A Phase 2 interventional study of IMC-1121B (ramucirumab) and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Eli Lilly and Company. Completed at 53 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 14 in phase 2, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 27th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2010, is one of 73 in phase 2, and was the 86th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMC-1121B + Pemetrexed + Carboplatin \[Area Under the Concentration Time Curve 6 (AUC 6)\] or Cisplatin
Biological: IMC-1121B (ramucirumab) · Drug: Pemetrexed · Drug: Carboplatin (AUC 6) · Drug: Cisplatin
Pemetrexed + Carboplatin (AUC 6) or Cisplatin
Drug: Pemetrexed · Drug: Carboplatin (AUC 6) · Drug: Cisplatin
IMC-1121B + Gemcitabine + Carboplatin \[Area Under the Concentration Time Curve 5 (AUC 5)\] or Cisplatin
Biological: IMC-1121B (ramucirumab) · Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin (AUC 5)
Gemcitabine + Carboplatin (AUC 5) or Cisplatin
Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin (AUC 5)
10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
Also known as: ramucirumab, IMC-1121B, LY3009806
500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
Day 1 of every 21-day cycle
75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
1000 mg/m² on Days 1 and 8 of every 21-day cycle
Day 1 of every 21-day cycle
Progression-Free Survival (PFS)
PFS was the time from randomization to the first objective progression as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1) or death from any cause, whichever occurred first. Progressive disease (PD) was defined as ≥20% increase in sum of diameter (SOD) of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 millimeters (mm); appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants alive and without disease progression were censored at the time of the last objective tumor assessment. Participants who did not progress and were lost to follow-up were censored at their last radiographic assessment. If no baseline or post baseline radiologic assessments were available, participants were censored at date of randomization.
Time frame: Randomization to PD or death (up to 24 months)
Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
Best overall response of CR or PR was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was defined as ≥30% decrease in SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)\*100.
Time frame: Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. If the participant was alive at the end of the follow-up period or was lost to follow-up, OS was censored on the last date the participant was known to be alive.
Time frame: Randomization to the date of death from any cause (up to 31.3 months)
Duration of Response (DOR)
DOR was measured from the time criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death. Response was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker level of non-target lesions. PR was defined as ≥30% decrease SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.
Time frame: Time of first response (CR or PR) until PD or death (up to 24 months)
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died
Data presented are the number of participants with at least 1 treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (SAE), as well as, the number of participants who died during the study. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). A summary of SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Day 1, Cycle 1 (3-week cycles) Up to 3 Years
Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]
DCR: percentage of participants with CR, PR, or SD using RECIST v 1.1 criteria. CR: disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR: ≥30% decrease in SOD of target lesions taking as reference baseline sum diameter. PD: ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference smallest sum of longest diameters recorded since treatment started and an absolute increase in sum diameter ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. SD: neither sufficient shrinkage to qualify for PR nor increase to qualify for PD. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR+SD/total number of participants)\*100.
Time frame: Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)
Change in Tumor Size (CTS)
CTS was defined as the log ratio of tumor size at 6 weeks to tumor size at baseline. CTS at 6 weeks=Log (Sum of Target Lesion Measurements at 6 Weeks)-Log (Sum of Target Lesion Measurements at Baseline).
Time frame: Baseline, 6 weeks
| Milestone | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Started | 71 | 69 | 69 | 71 |
| Received study drug | 69 | 67 | 63 | 71 |
| Completed | 60 | 64 | 62 | 67 |
| Not completed | 11 | 5 | 7 | 4 |
| Withdrew: Withdrawal by subject | 11 | 5 | 6 | 4 |
| Withdrew: Not meet inclusion/exclusion criteria | 0 | 0 | 1 | 0 |
PFS was the time from randomization to the first objective progression as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1) or death from any cause, whichever occurred first. Progressive disease (PD) was defined as ≥20% increase in sum of diameter (SOD) of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 millimeters (mm); appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants alive and without disease progression were censored at the time of the last objective tumor assessment. Participants who did not progress and were lost to follow-up were censored at their last radiographic assessment. If no baseline or post baseline radiologic assessments were available, participants were censored at date of randomization.
| months | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Progression-Free Survival (PFS) | 5.6 (4.0 to 5.7) | 7.2 (5.8 to 8.4) | 5.4 (4.7 to 5.7) | 5.6 (4.4 to 6.0) |
Best overall response of CR or PR was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was defined as ≥30% decrease in SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)\*100.
| percentage of participants | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] | 38.0 | 49.3 | 24.6 | 46.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. If the participant was alive at the end of the follow-up period or was lost to follow-up, OS was censored on the last date the participant was known to be alive.
| months | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Overall Survival (OS) | 10.4 (8.2 to 15.9) | 13.9 (10.0 to 17.8) | 11.3 (9.7 to 13.3) | 10.4 (7.8 to 14.8) |
DOR was measured from the time criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death. Response was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker level of non-target lesions. PR was defined as ≥30% decrease SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.
| months | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Duration of Response (DOR) | 4.5 (3.1 to 5.7) | 5.5 (4.4 to 5.8) | 4.3 (4.2 to 5.5) | 4.3 (3.3 to 5.6) |
Data presented are the number of participants with at least 1 treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (SAE), as well as, the number of participants who died during the study. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). A summary of SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Treatment-Emergent SAE | 38 | 44 | 29 | 39 |
| Treatment-Emergent Adverse Event | 68 | 67 | 63 | 71 |
| Deaths | 51 | 55 | 55 | 56 |
DCR: percentage of participants with CR, PR, or SD using RECIST v 1.1 criteria. CR: disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR: ≥30% decrease in SOD of target lesions taking as reference baseline sum diameter. PD: ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference smallest sum of longest diameters recorded since treatment started and an absolute increase in sum diameter ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. SD: neither sufficient shrinkage to qualify for PR nor increase to qualify for PD. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR+SD/total number of participants)\*100.
| percentage of participants | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)] | 70.4 (61.5 to 79.3) | 85.5 (78.5 to 92.5) | 66.7 (57.3 to 76.0) | 73.2 (64.6 to 81.9) |
CTS was defined as the log ratio of tumor size at 6 weeks to tumor size at baseline. CTS at 6 weeks=Log (Sum of Target Lesion Measurements at 6 Weeks)-Log (Sum of Target Lesion Measurements at Baseline).
| log ratio | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| Change in Tumor Size (CTS) | -0.2 ± 0.23 | -0.2 ± 0.22 | -0.3 ± 0.31 | -0.4 ± 0.39 |
Collected over Baseline through Study Completion (Up To 3 Years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pem + Carb or Cis (Non-Squamous) | 51/69 (73.9%) | 38/69 (55.1%) | 67/69 (97.1%) |
| Ram + Pem + Carb or Cis (Non-Squamous) | 55/67 (82.1%) | 44/67 (65.7%) | 66/67 (98.5%) |
| Gem + Carb or Cis (Squamous) | 55/63 (87.3%) | 29/63 (46%) | 62/63 (98.4%) |
| Ram + Gem + Carb or Cis (Squamous) | 56/71 (78.9%) | 39/71 (54.9%) | 71/71 (100%) |
| Event | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/69 | 4/67 | 2/63 | 8/71 |
| PneumoniaInfections and infestations | 6/69 | 1/67 | 6/63 | 7/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/69 | 2/67 | 2/63 | 6/71 |
| NauseaGastrointestinal disorders | 4/69 | 5/67 | 2/63 | 0/71 |
| VomitingGastrointestinal disorders | 4/69 | 5/67 | 1/63 | 0/71 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/69 | 5/67 | 0/63 | 0/71 |
| AnaemiaBlood and lymphatic system disorders | 1/69 | 1/67 | 2/63 | 5/71 |
| UnderdoseInjury, poisoning and procedural complications | 2/69 | 4/67 | 0/63 | 0/71 |
| DehydrationMetabolism and nutrition disorders | 2/69 | 4/67 | 1/63 | 3/71 |
| NeutropeniaBlood and lymphatic system disorders | 1/69 | 2/67 | 0/63 | 4/71 |
| Event | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 17/69 | 22/67 | 35/63 | 52/71 |
| FatigueGeneral disorders | 43/69 | 44/67 | 34/63 | 39/71 |
| AnaemiaBlood and lymphatic system disorders | 37/69 | 32/67 | 40/63 | 38/71 |
| NauseaGastrointestinal disorders | 39/69 | 35/67 | 36/63 | 27/71 |
| ThrombocytopeniaBlood and lymphatic system disorders | 15/69 | 22/67 | 27/63 | 36/71 |
| VomitingGastrointestinal disorders | 24/69 | 22/67 | 12/63 | 18/71 |
| Decreased appetiteMetabolism and nutrition disorders | 18/69 | 20/67 | 15/63 | 24/71 |
| ConstipationGastrointestinal disorders | 21/69 | 19/67 | 21/63 | 18/71 |
| DiarrhoeaGastrointestinal disorders | 19/69 | 19/67 | 12/63 | 9/71 |
| HeadacheNervous system disorders | 8/69 | 19/67 | 5/63 | 14/71 |
All randomized participants.
| Age, Customized(Participants) | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 37 | 27 | 34 | 135 |
| >=65 years | 34 | 32 | 40 | 37 | 143 |
| Missing Data | 0 | 0 | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) | Total |
|---|---|---|---|---|---|
| Female | 26 | 33 | 26 | 16 | 101 |
| Male | 45 | 36 | 43 | 55 | 179 |
| Ethnicity (NIH/OMB)(Participants) | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 1 | 0 | 6 |
| Not Hispanic or Latino | 70 | 65 | 68 | 71 | 274 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) | Total |
|---|---|---|---|---|---|
| White | 65 | 60 | 65 | 67 | 257 |
| Black | 2 | 8 | 1 | 4 | 15 |
| Asian | 4 | 1 | 1 | 0 | 6 |
| Other | 0 | 0 | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Pem + Carb or Cis (Non-Squamous) | Ram + Pem + Carb or Cis (Non-Squamous) | Gem + Carb or Cis (Squamous) | Ram + Gem + Carb or Cis (Squamous) | Total |
|---|---|---|---|---|---|
| United States | 71 | 69 | 42 | 41 | 223 |
| Canada | 0 | 0 | 4 | 1 | 5 |
| Belgium | 0 | 0 | 5 | 4 | 9 |
| Poland | 0 | 0 | 4 | 12 | 16 |
| Germany | 0 | 0 | 14 | 8 | 22 |
| United Kingdom | 0 | 0 | 0 | 5 | 5 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Sep 2010, a primary completion of Jan 2014 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 11 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Pemetrexed · Carboplatin · Gemcitabine
Carcinoma, Non-Small-Cell Lung →